You are here: Home » PTI Stories » National » News
Business Standard

Smile Train India Launches a Toll-free Cleft Helpline on National Cleft Day

Press Trust of India  |  NEW DELHI 

/ -- 200 medical professionals pledge support for Train's Right to campaign

To mark the second annual National Cleft Day, has officially launched the country's first toll-free national cleft helpline - Cleft Helpline. The helpline - 1800 103 8301, is accessible to people throughout who are looking for information about cleft treatment. The number also serves as a way for those in need to have access to invaluable referral information to the closest partner hospital, so they can receive 100%-free, quality and safe cleft treatment. The establishment of the cleft helpline would not have been possible without the generous support from GSK India, under their CSR initiatives.

Talking about the initiative, Mamta Carroll, - Asia, Smile Train shared, "Smile Train India has been committed to supporting world-class cleft treatment in India, and has already supported over 500,000 free cleft surgeries. On National Cleft Day, we further strengthen this resolve through these initiatives. We thank GSK for their generosity in this initiative."

Navneet Saluja, Managing Director, Ltd. said, "We are delighted to support Smile Train in their endeavour to provide free treatment for cleft. On the occasion of National Cleft Day, we dedicate a new toll-free helpline service to create awareness about cleft supported by Smile Train and their partner hospitals across India. GSK's expertise as a in oral health care and with Smile Train's knowledge we aim to ensure more children get quality treatment and care."

February 8 is observed as National Cleft Day by the Indian Society of Cleft Lip, and cleft charities in India. In addition, 200 medical professionals including surgeons, anaesthetists, speech therapists and orthodontists, pledged to bring smiles to children born with clefts, by signing Smile Train India's Right to Smile campaign. The Right to Smile campaign serves as a reminder to all that many children in India continue to live with untreated clefts due to challenges of awareness, accessibility and affordability.

To sign the pledge and show your support, please visit https://

About Smile Train

Smile Train empowers local medical professionals with training, funding, and resources to provide free cleft and comprehensive cleft care to children globally. We advance a and scalable global health model for cleft treatment, drastically improving children's lives, including their ability to eat, breathe, speak, and ultimately thrive. To learn more about how Smile Train's India's sustainable approach, please visit

About GlaxoSmithKline Consumer Healthcare Ltd.

is the in Indian Our flagship product Horlicks leads the market, while Boost is among the top three that India prefers. Our are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 3800 employees. GSK also markets and distributes a range of such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 800 distributors and a direct coverage of over 8

GSK Consumer Healthcare Ltd is an associate of of U.K, one of world's largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with products. Our goal is to build a global, growing business - we call a Fast-Moving Consumer Healthcare (FMCH) company - dedicated to with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

GSK Consumer Healthcare globally owns some of the world's best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, February 08 2019. 12:40 IST